1、Product Data SheetGallic acidCat. No.: HY-N0523CAS No.: 149-91-7分式: CHO分量: 170.12作靶點: COX; Reactive Oxygen Species; Apoptosis; Ferroptosis; Endogenous Metabolite作通路: Immunology/Inflammation; Metabolic Enzyme/Protease; NF-B; Apoptosis儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 mo

2、nth溶解性數(shù)據(jù)體外實驗 DMSO : 100 mg/mL (587.82 mM)* means soluble, but saturation unknown.SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 5.8782 mL 29.3910 mL 58.7820 mL5 mM 1.1756 mL 5.8782 mL 11.7564 mL10 mM 0.5878 mL 2.9391 mL 5.8782 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存式和期限：-80C

3、, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內(nèi)使，-20C 儲存時，請在 1 個內(nèi)使。體內(nèi)實驗請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍?。以下溶解案都請先按?In Vitro 式配制澄清的儲備液，再依次添加助溶劑：為保證實驗結(jié)果的可靠性，澄 的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubi

4、lity: 2.5 mg/mL (14.70 mM); Clear solution此案可獲得 2.5 mg/mL (14.70 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (14.70 mM); Clear solutionPage 1 of

5、 2 www.MedChemE此案可獲得 2.5 mg/mL (14.70 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合均勻。BIOLOGICAL ACTIVITY物活性 Gallic acid是COX-2 的抑制劑。IC & Target COX-2 Human Endogenous Metabolite(批量添加)體外研究 Gallic acid is an antioxidant which can inhibit both COX-21. After 18

6、 h treatment with Gallic acid, the number ofviable neutrophils is dramatically decreased from 40.3% to 27.7%, highly comparable with 26.4% for untreatedneutrophils. Gallic acid fails to attenuate isoproterenol-induced myocytolysis3.體內(nèi)研究 The food intake (2.60.08 g/day, p=0.69) and the body weight (2.

7、50.69 g, p=0.76) of the Gallic acid group do notdiffer significantly from those of the control group (food intake; 2.410.14 g/day and the body weight; 2.830.84g/day). The blood glucose tolerance in the Gallic acid group is significantly improved after 2 weeks of treatment. Theblood glucose tolerance

8、 of the Gallic acid group after a treatment period of 2 weeks is also significantly better thanthat of the control group at 90 and 120 min ( p0.05). The serum triglyceride concentration in the Gallic acid group(0.670.03 mM, p0.05) is significantly reduced relative to that of the control group (1.080

9、.20 mM). The totalcholesterol concentration is similar in the control (3.190.27 mM) and Gallic acid (3.010.18 mM) groups2.PROTOCOLCell Assay 3 Neutrophils are treated with 8 g/mL Gallic acid in RPMI1640/10% FBS for 3, 6, 9, and 18 h. At the end of Gallic acidtreatment, the cells are stained with Ann

10、exin V-FITC and PI according to manufacturers instructions. Briefly, the cellsare washed twice with ice-cold PBS and resuspended in 1 Binding Buffer at a concentration of 1106 cells/mL. Cellsuspensions (1105 cells in 100 L) are incubated with 5 L of Annexin V-FITC and 10 L PI in a 5 mL culture tube

11、atroom temperature for 20 min. The stained cells are immediately analyzed on flow cytometry system3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Five-week-old male C57BL/6 mice are used in this study. The animals are maintained in a temperatur

12、e-controlledAdministration 2 room at 22 C on a 12 h light-dark photocycle. The mice are divided into the control vehicle group and the Gallic acidgroup. For 2 weeks, the mice are administered intraperitoneal treatment on a daily basis with vehicle (10% alcohol,10% tween 80, and 80% saline) alone or

13、with 10 mg/kg Gallic acid. After this treatment, GTTs are again conducted,and the blood samples are taken for subsequent biochemical analysis. Over the experimental period, food intake andbody weight are measured on a daily basis2.MCE has not independently confirmed the accuracy of these methods. Th

14、ey are for reference only.REFERENCES1. Amaravani M, et al. COX-2 structural analysis and docking studies with gallic acid structural analogues. Springerplus. 2012 Dec;1(1):58.2. Bak EJ, et al. Gallic acid improves glucose tolerance and triglyceride concentration in diet-induced obesity mice. Scand J

15、 Clin Lab Invest. 2013Dec;73(8):607-14.Page 2 of 3 www.MedChemE3. Cheng Y, et al. Plant Natural Products Calycosin and Gallic Acid Synergistically Attenuate Neutrophil Infiltration and Subsequent Injury in Isoproterenol-Induced Myocardial Infarction: A Possible Role for Leukotriene B4 12-Hydroxydehydrogenase? Oxid Med Cell Longev. 2015;2015:4